Clinical Trials › NCT05925049
Active, Not Recruiting
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Sponsored by Biogen
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 400
Target enrollment
1
U.S. states
Jun 2023
Start date
Mar 2026
Expected completion
Interventions / Treatments
Natalizumab
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
Massachusetts1 site
Cambridge
MS centers in Massachusetts
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Massachusetts centersCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
